Takeda gets rights to Tesaro's niraparib

Tesaro Inc. (NASDAQ:TSRO) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) rights to develop and commercialize PARP inhibitor Zejula niraparib in Japan for all types of cancer, and in South Korea, Taiwan, Russia and Australia for oncology indications excluding prostate cancer.

Tesaro received $100 million up front and is eligible for up to $240 million in milestones, plus tiered royalties from the high teens to low thirties percentage. The Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) has worldwide rights, excluding Japan, to niraparib for prostate cancer...